Results 191 to 200 of about 1,142,469 (262)

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.
The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister   +23 more
wiley   +1 more source

Mehamudgaravati and type 2 diabetes mellitus

AYU (An international quarterly journal of research in Ayurveda), 2011
openaire   +3 more sources

eGFR slope as predictor of mortality in heart failure patients

ESC Heart Failure, Volume 12, Issue 2, Page 1217-1226, April 2025.
Abstract Aims Heart failure (HF) leads to an imbalance between heart and kidney function, resulting in poor outcomes. However, the prognostic significance of the estimated glomerular filtration rate (eGFR) trajectory in HF patients remains unclear. We analysed electronic health records (EHRs) of real‐world HF patients, assessing eGFR trajectories and ...
Sofie Verstreken, Monika Beles, Clara L. Oeste, Ana Moya, Imke Masuy, Riet Dierckx, Ward Heggermont, Jeroen Dauw, Dries Hens, Jozef Bartunek, Marc Vanderheyden   +10 more
wiley   +1 more source

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger, Elric Zweck, Constanze Moos, Patrick Horn, Fabian Voß, Heinz‐Peter Schultheiss, Jacob Eifer Møller, Udo Boeken, Hug Aubin, Artur Lichtenberg, Malte Kelm, Michael Roden, Amin Polzin, Ralf Westenfeld, Julia Szendroedi, Daniel Scheiber   +15 more
wiley   +1 more source

Hip fracture and type 2 diabetes mellitus

Osteoporosis and Sarcopenia
Ji-Young Seo
doaj   +1 more source

Association of anti-diabetic drugs and COVID-19 outcomes in patients with diabetes mellitus type 2 and cardiomyopathy. [PDF]

Sci Rep
Dimnjaković J, Buble T, Ivanko P, Pristaš I, Brborović O, Brborović H.   +5 more
europepmc   +1 more source

Metabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama   +12 more
wiley   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Effectiveness of Integrated Care for Diabetes Mellitus Type 2, Cardiovascular and Chronic Respiratory Diseases: A Systematic Review and Meta-Analysis. [PDF]

Int J Integr Care
Valentijn PP, Tymchenko L, Gruisen W, Bruls B, Abdalla Pereira F, Arends RY.   +5 more
europepmc   +1 more source

Takotsubo cardiomyopathy during armed conflict: A case series

ESC Heart Failure, Volume 12, Issue 2, Page 1494-1498, April 2025.
Sharon Bruoha, Artyom Star, Gili Givaty, Michael Shilo, Michael Friger, Vladimir Chitoroga, Hezzy Shmueli, Yigal Abramowitz, Elad Asher, Jamal Jafari, Vladimir Shlyakhover, Doron Zahger, Moti Haim, Chaim Yosefy   +13 more
wiley   +1 more source